Literature DB >> 1498517

Clinical and electrophysiological reports in a case of early onset myotonia congenita (Thomsen's disease) successfully treated with mexiletine.

M Ceccarelli1, B Rossi, G Siciliano, L Calevro, E Tarantino.   

Abstract

A sporadic event of myotonia congenita in a infant admitted to the Paediatric Clinic for frequent crises of apnoea, cyanosis, vomiting and difficult feeding is reported. EMG analysis was consistent with the dominant variety of myotonia congenita. Mexiletine therapy showed excellent results in reducing myotonic activity. It is worthwhile stressing that early symptoms may go unnoticed or may be misinterpreted and that information on the genetic form of the disease can be obtained also from the EMG analysis through a repetitive stimulation test.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1498517     DOI: 10.1111/j.1651-2227.1992.tb12271.x

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  7 in total

1.  Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1.

Authors:  E L Logigian; W B Martens; R T Moxley; M P McDermott; N Dilek; A W Wiegner; A T Pearson; C A Barbieri; C L Annis; C A Thornton; R T Moxley
Journal:  Neurology       Date:  2010-05-04       Impact factor: 9.910

Review 2.  Guidelines on clinical presentation and management of nondystrophic myotonias.

Authors:  Bas C Stunnenberg; Samantha LoRusso; W David Arnold; Richard J Barohn; Stephen C Cannon; Bertrand Fontaine; Robert C Griggs; Michael G Hanna; Emma Matthews; Giovanni Meola; Valeria A Sansone; Jaya R Trivedi; Baziel G M van Engelen; Savine Vicart; Jeffrey M Statland
Journal:  Muscle Nerve       Date:  2020-05-27       Impact factor: 3.217

Review 3.  Neurological channelopathies.

Authors:  T D Graves; M G Hanna
Journal:  Postgrad Med J       Date:  2005-01       Impact factor: 2.401

Review 4.  The non-dystrophic myotonias: molecular pathogenesis, diagnosis and treatment.

Authors:  E Matthews; D Fialho; S V Tan; S L Venance; S C Cannon; D Sternberg; B Fontaine; A A Amato; R J Barohn; R C Griggs; M G Hanna
Journal:  Brain       Date:  2009-11-16       Impact factor: 13.501

Review 5.  Drug treatment for myotonia.

Authors:  J Trip; G Drost; B G M van Engelen; C G Faber
Journal:  Cochrane Database Syst Rev       Date:  2006-01-25

Review 6.  Loss-of-function genetic diseases and the concept of pharmaceutical targets.

Authors:  Laurnet Ségalat
Journal:  Orphanet J Rare Dis       Date:  2007       Impact factor: 4.123

7.  Muscle channelopathies and electrophysiological approach.

Authors:  Ajith Cherian; Neeraj N Baheti; Abraham Kuruvilla
Journal:  Ann Indian Acad Neurol       Date:  2008-01       Impact factor: 1.383

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.